IGC Pharma
7 hedge funds and large institutions have $215K invested in IGC Pharma in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
1,767% more capital inflows, than outflows
Capital inflows: $187K | Capital outflows: $10K
0.68% more ownership
Funds ownership: 0.59% → 1.27% (+0.68%)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$122K |
| 2 |
Virtu Financial
New York
|
+$43.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thompson Davis & Co
Richmond,
Virginia
|
-$10K |
IGC Hedge Fund Activity: Q1 2018 in Review
7 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2018, worth a combined $215K — up 30% from $166K a quarter earlier.
Fund positioning in IGC was balanced in Q1 2018: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $122K. The largest seller was Thompson Davis & Co, exiting entirely with an estimated $10K sold.
- 7 institutional investors held IGC Pharma (IGC) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $215K of IGC Pharma stock for Q1 2018, up 30% quarter-over-quarter.
- 1 fund opened new IGC Pharma positions in Q1 2018 and 1 closed out, a net change of 0 holders.
- The largest IGC Pharma buyer in Q1 2018 was Citadel Advisors, an estimated $122K added.
- The largest IGC Pharma seller in Q1 2018 was Thompson Davis & Co, an estimated $10K sold.
Based on aggregated 13F filings for Q1 2018.